Page 2120 - Williams Hematology ( PDFDrive )

2094 Part XII: Hemostasis and Thrombosis Chapter 121: Acquired Qualitative Platelet Disorders 2095

528. Gabel J, Hakimi CS, Westerberg M, et al: Retransfusion of cardiotomy suction blood 557. Walker ID, Davidson JF, Faichney A, et al: A double-blind study of prostacyclin in car-
impairs haemostasis: Ex vivo and in vivo studies. Scand Cardiovasc J 47(6):368–376, diopulmonary bypass surgery. Br J Haematol 49:415–423, 1981.
2013. 558. Society of Thoracic Surgeons Blood Conservation Guideline Task F, Ferraris VA, Brown
529. Kestin AS, Valeri CR, Khuri SF, et al: The platelet function defect of cardiopulmonary JR, Despotis GJ, et al: 2011 update to the Society of Thoracic Surgeons and the Society
bypass. Blood 82:107–117, 1993. of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines.
530. Weksler BB, Pett SB, Alonso D, et al: Differential inhibition of aspirin of vascular pros- Ann Thorac Surg 91(3):944–982, 2011.
taglandin synthesis in atherosclerotic patients. N Engl J Med 308:800–805, 1983. 559. O’Connell KA, Wood JJ, Wise RP, et al: Thromboembolic adverse events after use of
531. Levy JH: Pharmacologic preservation of the hemostatic system during cardiac surgery. recombinant human coagulation factor VIIa. JAMA 295(3):293–298, 2006.
Ann Thorac Surg 72(5):S1814–S1820, 2001. 560. Goodnough LT, Levy JH: Off-label use of recombinant human factor VIIa. Ann Thorac
532. Tabuchi N, de Haan J, Boonstra PW, van Oeveren W: Activation of fibrinolysis in Surg 98(2):393–395, 2014.
the pericardial cavity during cardiopulmonary bypass. J Thorac Cardiovasc Surg 561. Giannini E, Botta F, Borro P, et al: Relationship between thrombopoietin serum lev-
106(5):828–833, 1993. els and liver function in patients with chronic liver disease related to hepatitis C virus
533. Hunt BJ, Parratt RN, Segal HC, et al: Activation of coagulation and fibrinolysis during infection. Am J Gastroenterol 98(11):2516–2520, 2003.
cardiothoracic operations. Ann Thorac Surg 65(3):712–718, 1998. 562. Nussmeier NA, Whelton AA, Brown MT, et al: Complications of the COX-2 inhibi-
534. Rapaport SI: Preoperative hemostatic evaluation: Which tests, if any? Blood 61(2):229– tors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352(11):1081–1091,
231, 1983. 2005.
535. Magovern JA, Sakert T, Benckart DH, et al: A model for predicting transfusion after 563. Mangano DT, Tudor IC, Dietzel C: The risk associated with aprotinin in cardiac sur-
coronary artery bypass grafting [see comments]. Ann Thorac Surg 61(1):27–32, 1996. gery. N Engl J Med 354(4):353–365, 2006.
536. Simon TA, Akl BF, Murphy W: Controlled trial of routine administration of platelet 564. Schneeweiss S, Seeger JD, Landon J, Walker AM: Aprotinin during coronary-artery
concentrates in cardiopulmonary bypass surgery. Ann Thorac Surg 37:359, 1987. bypass grafting and risk of death. N Engl J Med 358(8):771–783, 2008.
537. Wasser MN, Houbiers JG, D’Amaro J, et al: The effect of fresh versus stored blood on 565. Shaw AD, Stafford-Smith M, White WD, et al: The effect of aprotinin on outcome after
post-operative bleeding after coronary bypass surgery: A prospective randomized coronary-artery bypass grafting. N Engl J Med 358(8):784–793, 2008.
study. Br J Haematol 72:81–84, 1989. 566. Fergusson DA, Hebert PC, Mazer CD, et al: A comparison of aprotinin and lysine ana-
538. Sowade O, Warnke H, Scigalla P, et al: Avoidance of allogeneic blood transfusions by logues in high-risk cardiac surgery. N Engl J Med 358(22):2319–2331, 2008.
treatment with epoetin beta (recombinant human erythropoietin) in patients undergo- 567. Amitrano L, Guardascione MA, Brancaccio V, Balzano A: Coagulation disorders in
ing open-heart surgery. Blood 89(2):411–418, 1997. liver disease. Semin Liver Dis 22(1):83–96, 2002.
539. Shimpo H, Mizumoto T, Onoda K, et al: Erythropoietin in pediatric cardiac surgery: 568. Lisman T, Porte RJ: Rebalanced hemostasis in patients with liver disease: Evidence and
Clinical efficacy and effective dose. Chest 111(6):1565–1570, 1997. clinical consequences. Blood 116(6):878–885, 2010.
540. Schmoeckel M, Nollert G, Mempel M, et al: Effects of recombinant human erythropoi- 569. Hugenholtz GC, Adelmeijer J, Meijers JC, et al: An unbalance between von Willebrand
etin on autologous blood donation before open heart surgery. Thorac Cardiovasc Surg factor and ADAMTS13 in acute liver failure: Implications for hemostasis and clinical
41(6):364–368, 1993. outcome. Hepatology 58(2):752–761, 2013.
541. Axford TC, Dearani JA, Ragno G, et al: Safety and therapeutic effectiveness of reinfused 570. Krauss JS, Jonah MH: Platelet dysfunction (thrombocytopathy) in extra-hepatic biliary
shed blood after open heart surgery [see comments]. Ann Thorac Surg 57(3):615–622, obstruction. South Med J 75(4):506–507, 1982.
1994. 571. Hillbom M, Muuronen A, Neiman J: Liver disease and platelet function in alcoholics.
542. Griffith LD, Billman GF, Daily PO, Lane TA: Apparent coagulopathy caused by infu- Br Med J 295:581, 1987.
sion of shed mediastinal blood and its prevention by washing of the infusate [see com- 572. Stein SF, Harker LA: Kinetic and functional studies of platelets, fibrinogen, and plas-
ments]. Ann Thorac Surg 47(3):400–406, 1989. minogen in patients with hepatic cirrhosis. J Lab Clin Med 99:217, 1982.
543. Hsu LC: Heparin-coated cardiopulmonary bypass circuits: Current status. Perfusion 573. Violi F, Leo R, Vezza E, et al: Bleeding time in patients with cirrhosis: Relation with
16(5):417–428, 2001. degree of liver failure and clotting abnormalities. C.A.L.C. Group. Coagulation Abnor-
544. Spijker HT, Graaff R, Boonstra PW, et al: On the influence of flow conditions and wet- malities in Cirrhosis Study Group. J Hepatol 20(4):531–536, 1994.
tability on blood material interactions. Biomaterials 24(26):4717–4727, 2003. 574. Livio M, Mannucci PM, Vigano G, et al: Conjugated estrogens for the management of
545. Lappegard KT, Fung M, Bergseth G, et al: Effect of complement inhibition and heparin bleeding associated with renal failure. N Engl J Med 315:731, 1986.
coating on artificial surface-induced leukocyte and platelet activation. Ann Thorac Surg 575. Svensson PJ, Bergqvist PB, Juul KV, Berntorp E: Desmopressin in treatment of hae-
77(3):932–941, 2004. matological disorders and in prevention of surgical bleeding. Blood Rev 28(3):95–102,
546. Weerwind PW, Caberg NE, Reutelingsperger CP, et al: Exposure of procoagulant 2014.
phospholipids on the surface of platelets in patients undergoing cardiopulmonary 576. Pareti FI, Capitanio A, Mannucci L: Acquired storage pool disease in platelets during
bypass using non-coated and heparin-coated extracorporeal circuits. Int J Artif Organs disseminated intravascular coagulation. Blood 48:511, 1976.
25(8):770–776, 2002. 577. Pareti FI, Capitanio A, Mannucci L, Ponticelli C, Mannucci PM: Acquired dysfunction
547. Johnell M, Elgue G, Larsson R, et al: Coagulation, fibrinolysis, and cell activation in due to the circulation of “exhausted” platelets. Am J Med 69:235–240, 1980.
patients and shed mediastinal blood during coronary artery bypass grafting with a new 578. Solum NO, Rigollot C, Budzynski A, Marder VJ: A quantitative evaluation of the inhi-
heparin-coated surface. J Thorac Cardiovasc Surg 124(2):321–332, 2002. bition of platelet aggregation by low molecular weight degradation products of fibrino-
548. Linneweber J, Chow TW, Kawamura M, et al: In vitro comparison of blood pump gen. Br J Haematol 24:619, 1973.
induced platelet microaggregates between a centrifugal and roller pump during cardio- 579. Stoff JS, Stemerman M, Steer M, Salzman E, Brown RS: A defect in platelet aggregation
pulmonary bypass. Int J Artif Organs 25(6):549–555, 2002. in Bartter’s syndrome. Am J Med 68:171–180, 1980.
549. Despotis GJ, Avidan MS, Hogue CW Jr: Mechanisms and attenuation of hemostatic 580. van Wersch J, Rodriques Pereira R. Platelet aggregation in six families with Bartter’s
activation during extracorporeal circulation. Ann Thorac Surg 72(5):S1821–S1831, syndrome. Clin Chim Acta 130:363–368, 1983.
2001. 581. Nusing RM, Reinalter SC, Peters M, et al: Pathogenetic role of cyclooxygenase-2
550. Nuttall GA, Erchul DT, Haight TJ, et al: A comparison of bleeding and transfusion in in hyperprostaglandin E syndrome/antenatal Bartter syndrome: Therapeutic use
patients who undergo coronary artery bypass grafting via sternotomy with and without of the cyclooxygenase-2 inhibitor nimesulide. Clin Pharmacol Ther 70(4):384–390,
cardiopulmonary bypass. J Cardiothorac Vasc Anesth 17(4):447–451, 2003. 2001.
551. Mariani MA, Gu YJ, Boonstra PW, et al: Procoagulant activity after off-pump coronary 582. Hebert SC: Bartter syndrome. Curr Opin Nephrol Hypertens 12(5):527–532, 2003.
operation: Is the current anticoagulation adequate? Ann Thorac Surg 67(5):1370–1375, 583. Zapata JC, Cox D, Salvato MS: The role of platelets in the pathogenesis of viral hemor-
1999. rhagic fevers. PLoS Negl Trop Dis 8(6):e2858, 2014.
552. Paparella D, Galeone A, Venneri MT, et al: Activation of the coagulation system during 584. Lim SH, Tan CE, Agasthian T, Chew LS: Acquired platelet dysfunction with eosino-
coronary artery bypass grafting: Comparison between on-pump and off-pump tech- philia: Review of seven adult cases. J Clin Pathol 42:950–952, 2014, 1989.
niques. J Thorac Cardiovasc Surg 131(2):290–297, 2006. 585. Poon MC, Ng SC, Coppes MJ: Acquired platelet dysfunction with eosinophilia in white
553. Vallely MP, Bannon PG, Bayfield MS, et al: Quantitative and temporal differences in children. J Pediatr 126(6):959–961, 1995.
coagulation, fibrinolysis and platelet activation after on-pump and off-pump coronary 586. Laosombat V, Wongchanchailert M, Sattayasevana B, et al: Acquired platelet
artery bypass surgery. Heart Lung Circ 18(2):123–130, 2009. dysfunction with eosinophilia in children in the south of Thailand. Platelets 12(1):5–14,
554. Hackmann T, Gascoyne R, Naiman SC, et al: A trial of desmopressin to reduce blood 2001.
loss in uncomplicated cardiac surgery. N Engl J Med 321:1437–1444, 1989. 587. Szczeklik A, Milner PC, Birch J, et al: Prolonged bleeding time, reduced platelet aggre-
555. Seear MD, Wadsworth LD, Rogers PC, et al: The effect of desmopressin acetate gation, altered PAF-acether sensitivity and increased platelet mass are a trait of asthma
(DDAVP) on postoperative blood loss after cardiac operations in children [see com- and hay fever. Thromb Haemost 56:283–287, 1986.
ments]. J Thorac Cardiovasc Surg 98(2):217–219, 1989. 588. Carvalho AC, Quinn DA, DeMarinis SM, et al: Platelet function in acute respiratory
556. Wademan BH, Galvin SD: Desmopressin for reducing postoperative blood loss and failure. Am J Hematol 25:377–388, 1987.
transfusion requirements following cardiac surgery in adults. Interact Cardiovasc Tho- 589. Bracey AW, Wu AH, Aceves J, et al: Platelet dysfunction associated with Wilms tumor
rac Surg 18(3):360–370, 2014. and hyaluronic acid. Am J Hematol 24:247–257, 1987.

Kaushansky_chapter 121_p2073-2096.indd 2095 9/18/15 10:28 AM